Does methotrexate (MTX) affect menstruation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Methotrexate's Effects on Menstruation

Methotrexate can affect menstruation, with evidence showing it may cause menstrual abnormalities including amenorrhea in some patients, particularly with long-term use. 1

Mechanism and Evidence

Methotrexate (MTX) is a competitive inhibitor of dihydrofolate reductase that affects rapidly dividing cells and has immunosuppressive effects 2. Its impact on menstruation appears to be related to several factors:

  • Higher levels of FSH (follicle-stimulating hormone), which indicate diminished ovarian reserve, have been shown to have a significant positive relationship with:

    • Disease activity
    • Cumulative dose of methotrexate
    • Duration of methotrexate therapy 1
  • A case report documented unexplained secondary amenorrhea in a 44-year-old woman with rheumatoid arthritis after long-term methotrexate use 3

  • Research has shown that methotrexate may target actively proliferating cells including oocytes and granulosa cells, potentially impairing ovarian reserve 1

Clinical Considerations

Risk Factors for Menstrual Abnormalities

  • Age: Older premenopausal patients are more likely to experience menstrual abnormalities, though they can occur in younger patients as well 4
  • Cumulative dose: Higher cumulative doses correlate with increased FSH levels 1
  • Duration of therapy: Longer treatment duration is associated with higher FSH levels 1
  • Disease activity: Higher disease activity (as measured by DAS 28 in rheumatoid arthritis) is significantly associated with FSH level changes 1

Reproductive Implications

Methotrexate has significant implications for reproductive health:

  • It is absolutely contraindicated during pregnancy (FDA pregnancy category X) due to teratogenic effects 5, 6
  • Women must use effective contraception while taking methotrexate 5
  • Methotrexate should be discontinued at least 3 months before attempting conception 5
  • Breastfeeding is contraindicated during methotrexate therapy 5

Management Recommendations

For patients experiencing menstrual abnormalities while on methotrexate:

  • Monitor for menopausal symptoms, which have been reported in over half (53.1%) of reproductive-age women taking methotrexate, especially hot flushes 1

  • Consider hormonal evaluation including FSH and LH levels if menstrual abnormalities occur 1

  • Discuss family planning well in advance of conception attempts, as methotrexate requires discontinuation at least 3 months before attempting pregnancy 5

  • For patients with severe menstrual abnormalities where quality of life is significantly affected, consider:

    • Evaluating disease activity and methotrexate dosing
    • Discussing alternative treatment options with similar efficacy but less impact on menstruation
    • Referral to gynecology for further evaluation and management

Monitoring Recommendations

For patients of reproductive age on methotrexate:

  • Regular assessment of menstrual patterns during follow-up visits
  • Evaluation of menopausal symptoms
  • Consideration of hormonal testing if menstrual abnormalities develop
  • Regular pregnancy tests for women of childbearing potential 5

Conclusion

Methotrexate can affect menstruation through its impact on ovarian function, with effects that appear to be related to cumulative dose, duration of therapy, and disease activity. Clinicians should monitor for menstrual abnormalities in patients taking methotrexate and provide appropriate counseling regarding reproductive implications.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Unexplained amenorrhea in a patient taking methotrexate for the treatment of rheumatoid arthritis.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2010

Research

The risk of premature menopause induced by chemotherapy for early breast cancer.

Journal of women's health & gender-based medicine, 1999

Guideline

Reproductive Health and Methotrexate

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.